This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2018 Dec;127(6):1292-1294.

doi: 10.1213/ANE.0000000000003852.

Clarifying Misconceptions About US Food and Drug Administration Unapproved Drugs Program

Donald D Ashley¹

Affiliations

PMID: 30433920
DOI: 10.1213/ANE.0000000000003852

Editorial

Clarifying Misconceptions About US Food and Drug Administration Unapproved Drugs Program

Donald D Ashley. Anesth Analg. 2018 Dec.

. 2018 Dec;127(6):1292-1294.

doi: 10.1213/ANE.0000000000003852.

Author

Donald D Ashley¹

Affiliation

¹ From the Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.

PMID: 30433920
DOI: 10.1213/ANE.0000000000003852

No abstract available

PubMed Disclaimer

Comment in

Editorial by US Food and Drug Administration Attorney Fails to Address Core and Ongoing Issues Seen With Vasopressin Market.
Almeter PJ, Hessel EA 2nd, Labuhn JA, Morris PE. Almeter PJ, et al. Anesth Analg. 2019 Apr;128(4):e55-e56. doi: 10.1213/ANE.0000000000004042. Anesth Analg. 2019. PMID: 30730466 No abstract available.

Comment on

US Food and Drug Administration Disruption of Generic Drug Market Increases Hospital Costs.
Almeter PJ, Labuhn JA, Morris PE, Hessel EA 2nd. Almeter PJ, et al. Anesth Analg. 2018 Dec;127(6):1414-1420. doi: 10.1213/ANE.0000000000003589. Anesth Analg. 2018. PMID: 29944521

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wolters Kluwer